Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting (Angiolipo)

This study is currently recruiting participants. (see Contacts and Locations)
Verified April 2014 by University Hospital, Caen
Sponsor:
Information provided by (Responsible Party):
University Hospital, Caen
ClinicalTrials.gov Identifier:
NCT01932021
First received: April 18, 2013
Last updated: April 8, 2014
Last verified: April 2014

April 18, 2013
April 8, 2014
April 2013
April 2014   (final data collection date for primary outcome measure)
Treatment of hypertensive leg ulcer by adipose tissue grafting [ Time Frame: one year ] [ Designated as safety issue: Yes ]
The objective of this study is to evaluate pain
Same as current
Complete list of historical versions of study NCT01932021 on ClinicalTrials.gov Archive Site
treatment of angiodermatitis necrotitis by lipofilling [ Time Frame: one year ] [ Designated as safety issue: Yes ]

Other objectives are to evaluate the tolerance, in terms of pain and side effects, and secondly, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound.

The objective also covers the measurement of changes in the appearance of the wound, with an expected decrease of relative areas of fibrin and necrosis. The percentage of wound healing and wound area was measured at each visit, a curve will be performed for each patient to assess the speed of healing and the appearance of the wound will be notified.

Same as current
Not Provided
Not Provided
 
Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting
Treatment of Hypertensive Leg Ulcer by Adipose Tissue Grafting

The hypertensive leg ulcer is a very painful leg related to acute skin microangiopathy. It occurs in patients older than 60 years followed for hypertension. Clinical diagnosis requires eliminating other causes arterial ulcers, cryoglobulinemia, thrombophilia, cholesterol crystal emboli, vasculitis associated with hepatitis C, myeloproliferative disorders and ulcers associated with the Hydrea ® outlet.

There is no treatment of the ulcer because conventional treatments are ineffective. The pain has subsided by analgesics III. Other treatments are not effective outside skin grafts to be repeated because they necrotic regularly. In a prospective uncontrolled study, 11 patients healed through autohemotherapy.

Ineffective treatment of this painful condition and efficiency of these cells to the damaged tissue, due to the secretion of many bioactive molecules, led us to propose subcutaneous injections of autologous fat to change the wound bed, promote healing and eliminate pain. This treatment should help to avoid long-term hospitalization (about 15 days) that can lead to physical and psychological degradation of these elderly patients.

The investigators propose an open clinical study of 10 patients with a single-center recruitment (CHU Caen). The study took place over a period of 18 months with a 12-month recruitment and follow-up of 6 months for each patient.

The purpose of this study was to evaluate the one hand, tolerance, in terms of pain and side effects, and, on the other hand, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound. The measure of effectiveness will also focus on the changing appearance of the wound, including the relative areas of fibrin, necrosis and budding. These efficiency measures (area ratio) will be done through a computer program (CANVAS ®) on photographs taken at each assessment time.

Eventually, if this study was to demonstrate the effectiveness of this treatment lipofilling, it would be possible to perform a multicenter study on a large number of patients to demonstrate the effectiveness, in terms of wound healing that the pain it causes and offer a shorter hospital stay, and in parallel, this approach should improve the pathophysiology of ulceration (translational research).

The objective of this study was to evaluate the one hand, tolerance, in terms of pain and side effects, and secondly, the effectiveness of this therapeutic approach, in terms of healing of the ulcer assuming a decrease in the size of the estimated at least 40% at 3 months wound. The objective also covers the measurement of changes in the appearance of the wound, with an expected decrease of relative areas of fibrin and necrosis. The percentage of wound healing and wound area was measured at each visit, a curve will be performed for each patient to assess the speed of healing and the appearance of the wound will be notified.

Interventional
Not Provided
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Skin Ulcer
Procedure: adipose tissue grafting
Experimental: adipose tissue grafting
Intervention: Procedure: adipose tissue grafting
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruiting
10
December 2014
April 2014   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Patients over 18 years with a necrotic ulcer or angiodermatitis Martorell.
  • Recipient of the system of social security.
  • Ulceration sudden onset peripheral Livedoid border, on superficial leg without bone or tendon exposure.
  • IPS Index (systolic pressure)> 0.8 with pedal pulses.
  • Wound area less than 300 cm2 surface measurement with Canvas ® software from a photograph of the wound next to which there is a calibration strip.
  • Patients with hypertension.
  • Patient was informed of the study and having signed an informed consent.

Exclusion Criteria:

  • Severe distal arteritis (arteritis of large arteries).
  • Histological vasculitis.
  • Collagen (THE BY, scleroderma).
  • Blood Pathology: Cryoglobulinemia, Polycythemia.
  • Hepatitis A, B and C, HIV and syphilis infection
  • Thrombophilia (search for markers during the initial assessment in patients with a history of phlebitis or miscarriage).
  • Hyperthyroidism.
  • Patient treated with Hydrea (favoring the occurrence of ulcers).
  • Patient participating in another study to treat the wound concerned.
  • Topics minors, pregnant women, persons deprived of liberty, adults under legal protection unable to consent.
Both
18 Years and older
No
Contact: Anne Dompmartin-Blanchère +33 2 31 27 25 09 dompmartin-a@chu-caen.fr
Contact: Marianne Chopinaud +33 6 85 82 29 42 mariannechopinaud@hotmail.com
France
 
NCT01932021
2012-A01613-40
Yes
University Hospital, Caen
University Hospital, Caen
Not Provided
Principal Investigator: Anne Dompmartin, MD University Hospital, Caen
University Hospital, Caen
April 2014

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP